yingweiwo

Ramipril (HOE-498)

Alias: HOE-498; Altace; Carasel;HOE498;Ramace; Zabien;HOE 498;Tritace; Ramace; Triatec; Tritace; Vesdil;
Cat No.:V1783 Purity: ≥98%
Ramipril (HOE-498; Altace; Carasel; Ramace; Zabien; Tritace; Ramace; Triatec; Tritace; Vesdil) is a potent angiotensin-converting enzyme (ACE) inhibitor with anti-hypertensive effects.
Ramipril (HOE-498)
Ramipril (HOE-498) Chemical Structure CAS No.: 87333-19-5
Product category: RAAS
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
100mg
500mg
1g
2g
10g
Other Sizes

Other Forms of Ramipril (HOE-498):

  • Ramipril-d5 (ramipril d5)
  • Ramipril-d3 (ramipril-d3)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Ramipril (HOE-498; Altace; Carasel; Ramace; Zabien; Tritace; Ramace; Triatec; Tritace; Vesdil) is a potent angiotensin-converting enzyme (ACE) inhibitor with anti-hypertensive effects. It inhibits ACE with an IC50 of 5 nM and has been approved for hypertension treatment. Ramipril is a produg that has to be activated by hydrolysis to the active metabolite Ramiprilat. Studies indicate that Ramipril is a more potent inhibitor in comparison to Zofenopril (sc-208496). Acute coronary syndrome investigations demonstrate that Ramipril increases IL-10, and decreases the levels of MCP-1 and IL-18.

Biological Activity I Assay Protocols (From Reference)
ln Vitro
Angiotensin-converting enzyme (ACE) inhibitor ramipril (HOE-498) has an IC50 of 5 nM[1]. However, in endothelial cells expressing an S1270A ACE mutant or in ACE-deficient cells, ramipril (HOE-498) is unable to activate JNK or boost the nuclear accumulation of c-Jun. Instead, it increases the activity of ACE-associated CK2 and the phosphorylation of ACE Ser1270 in cultured endothelial cells. Long-term Ramipril use raises ACE expression in mouse lung in vivo and primary cultures of human endothelial cells, a phenomenon that can be avoided by pretreating with the JNK inhibitor SP600125[2].
ln Vivo
In contrast to the apoptosis effect in vitro, chronic in vivo administration of Ramipril (HOE-498) to rats at a dosage that has similar hypotensive effects in vitro HUVECs considerably lowers the rate of LPS-induced apoptosis relative to the other ACE inhibitors[3 [4].
Animal Protocol
Dissolved in distilled water by using gum arabic (10% w/v); 0.03-10 mg/kg; Oral gavage
Male spontaneously hypertensive rats
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
The extent of absorption is at least 50-60%.. Food decreases the rate of absorption from the GI tract without affecting the extent of absorption. The absolute bioavailabilities of ramipril and ramiprilat were 28% and 44%, respectively, when oral administration was compared to intravenous administration. The serum concentration of ramiprilat was unchanged when capsules were opened and the contents dissolved in water, dissolved in apple juice, or suspended in apple sauce.
Following oral administration, about 60% of the dose is eliminated in the urine as unchanged ramipril (<2%) and its metabolites. About 40% of the dose is found in the feces, representing both unabsorbed drug and drugs and metabolites eliminated via biliary excretion. The urinary excretion of ramipril may be reduced in patients with impaired renal function.
The renal clearance of ramipril and ramiprilat was reported to be 7.2 and 77.4 mL/min/1.73m2. The mean renal clearance of ramipril and ramiprilat is reported to be 10.7 and 126.8 mL/min in healthy elderly patients with normal renal function, additionally the Cmax of ramiprilat is approximately 20% higher in this population. While the pharmacokinetics of ramipril appear unaffected by reduced renal function, the plasma concentration and half-life of ramiprilat are increased. In patient's with hepatic failure the concentration of ramipril is initially increased while the tmax of ramiprilat is prolonged due to a reduced ability to metabolize the drug. However, steady state concentrations of ramiprilat are the same in hepatic failure as in healthy patients.
/MILK/ Ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk.
Following oral administration of ramipril, peak plasma concentrations (Cmax) of ramipril are reached within 1 hour. The extent of absorption is at least 50% to 60%, and is not significantly influenced by the presence of food in the gastrointestinal tract, although the rate of absorption is reduced.
Plasma concentrations of ramiprilat decline in a triphasic manner (initial rapid decline, apparent elimination phase, terminal elimination phase). The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours. Because of its potent binding to ACE and slow dissociation from the enzyme, ramiprilat shows two elimination phases. The apparent elimination phase corresponds to the clearance of free ramiprilat and has a half-life of 9 to 18 hours. The terminal elimination phase has a prolonged half-life (>50 hours) and probably represents the binding/dissociation kinetics of the ramiprilat/ACE complex. It does not contribute to the accumulation of the drug. After multiple daily doses of ramipril 5 mg to 10 mg, the half-life of ramiprilat concentrations within the therapeutic range was 13 to 17 hours. /Ramiprilat/
Plasma concentrations of ramipril and ramiprilat increase with increased dose, but are not strictly dose-proportional. The 24-hour AUC for ramiprilat, however, is dose-proportional over the 2.5 mg to 20 mg dose range. The absolute bioavailabilities of ramipril and ramiprilat were 28% and 44%, respectively, when 5 mg of oral ramipril was compared with the same dose of ramipril given intravenously.
For more Absorption, Distribution and Excretion (Complete) data for Ramipril (7 total), please visit the HSDB record page.
Metabolism / Metabolites
Hepatic metabolism accounts for 75% of total ramipril metabolism. 25% of hepatic metabolism produces the active metabolite ramiprilat via liver esterase enzymes. 100% of renal metabolism converts ramipril to ramiprilat. Other metabolites, diketopiperazine ester, the diketopiperazine acid, and the glucuronides of ramipril and ramiprilat, are inactive.
Cleavage of the ester group (primarily in the liver) converts ramipril to its active diacid metabolite, ramiprilat. Peak plasma concentrations of ramiprilat are reached 2 to 4 hours after drug intake. The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 ug/mL to 10 mcg/mL.
After oral administration to dogs, ramipril is rapidly converted via de-esterification into ramiprilat. Bioavailability of ramiprilat after a dose of 0.25 mg/kg per day of ramipril is approximately 6.7%.
Ramipril is a prodrug and has little pharmacologic activity until hydrolyzed in the liver to ramiprilat.
Ramipril is almost completely metabolized to ramiprilat, which has about 6 times the angiotensin-converting enzyme (ACE) inhibitory activity of ramipril, and to the diketopiperazine ester, the diketopiperazine acid, and the glucuronides of ramipril and ramiprilat, all of which are inactive.
Biological Half-Life
Plasma concentrations of ramiprilat decline in a triphasic manner. Initial rapid decline represents distribution into tissues and has a half life of 2-4 hours. The half life of the apparent elimination phase is 9-18 hours, which is thought to represent clearance of free drug. The half-life of the terminal elimination phase is > 50 hours and thought to represent clearance of drug bound to ACE due to its slow dissociation. The half life of ramiprilat after multiple daily doses (MDDs) is dose-dependent, ranging from 13-17 hours with 5-10 mg MDDs to 27-36 hours for 2.5 mg MDDs.
Plasma concentrations of ramiprilat /metabolite of ramipril/ decline in a triphasic manner (initial rapid decline, apparent elimination phase, terminal elimination phase). The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours. Because of its potent binding to ACE and slow dissociation from the enzyme, ramiprilat shows two elimination phases. The apparent elimination phase corresponds to the clearance of free ramiprilat and has a half-life of 9 to 18 hours. The terminal elimination phase has a prolonged half-life (>50 hours) and probably represents the binding/dissociation kinetics of the ramiprilat/ACE complex. It does not contribute to the accumulation of the drug. After multiple daily doses of ramipril 5 mg to 10 mg, the half-life of ramiprilat concentrations within the therapeutic range was 13 to 17 hours. /Ramiprilat/
Toxicity/Toxicokinetics
Toxicity Summary
IDENTIFICATION AND USE: Ramipril is a prodrug and has little pharmacologic activity until hydrolyzed in the liver to ramiprilat. It is an angiotensin-converting enzyme (ACE) inhibitor indicated for the treatment of hypertension. It is also used for stable patients with demonstratable congestive heart failure within the first few days of sustaining acute myocardial infarction. HUMAN STUDIES: Rare ACE inhibitor-associated clinical syndrome manifested initially by cholestatic jaundice may occur. It may progress to fulminant hepatic necrosis and is potentially fatal. Patients receiving an ACE inhibitor, including ramipril, who develop jaundice or marked elevations in hepatic enzymes should discontinue the drug and receive appropriate monitoring. Sensitivity reactions, including anaphylactic reactions and angioedema (including laryngeal or tongue edema) are potentially fatal. Head and neck angioedema involving the tongue, glottis, or larynx may cause airway obstruction. If laryngeal stridor or angioedema of the face, tongue, or glottis occurs, ramipril should be discontinued and appropriate therapy (e.g., epinephrine) should be initiated immediately. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue ramipril as soon as possible. No mutagenic activity was detected in the unscheduled DNA synthesis in a human cell line. ANIMAL STUDIES: No evidence of a tumorigenic effect was found when ramipril was given by gavage to rats for up to 24 months at doses of up to 500 mg/kg/day or to mice for up to 18 months at doses of up to 1000 mg/kg/day. A study in rats with dosages as great as 500 mg/kg/day did not produce adverse effects on fertility. Kidney organogenesis and functional development continue well into the postnatal period in the rat. A within-litter design was used to characterize renal susceptibility to an ACE inhibitor during the third week of life in rats. There were no treatment-related effects in rats dosed on PND 21. Following dosing on PND 14, dose-related increases were noted in mean serum urea nitrogen and/or creatinine levels on PND 17, but these measures recovered by PND 28. The interim changes were accompanied by macroscopic and microscopic changes in the kidneys on PND 17, including tubular hypoplasia, renal papillary edema, cortical tubular dilatation, hydronephrosis (pelvic dilatation) and tubular basophilia; renal anatomic changes were still evident and more severe on PND 28, 14 days after dosing. No mutagenic activity was detected in the Ames test in bacteria, the micronucleus test in mice or a forward gene-mutation assay in a Chinese hamster ovary cell line.
Hepatotoxicity
Ramipril, like other ACE inhibitors, has been associated with a low rate of serum aminotransferase elevations (
Likelihood score: C (probable rare cause of clinically apparent liver injury).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Because no information is available on the use of ramipril during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
Protein binding of ramipril is about 73% and that of ramiprilat about 56%. Protein binding is independent of concentration over the range of 0.1μg/mL-10μg/mL
Interactions
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of non-ateroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 (COX-2) inhibitors, with angiotensin-converting enzyme (ACE) inhibitors, including ramipril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving ramipril and NSAID therapy. The antihypertensive effect of ACE inhibitors, including ramipril, may be attenuated by NSAIDs.
Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.
Coadministration of ramipril with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.
Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. If this is not possible, reduce the starting dose.
References

[1]. Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR. J Hypertens, 2004. 22(3): p. 611-8.

[2]. Stevens, B.R., M.I. Phillips, and A. Fernandez, Ramipril inhibition of rabbit (Oryctolagus cuniculus) small intestinal brush border membrane angiotensin converting enzyme. Comp Biochem Physiol C, 1988. 91(2): p. 493-7.

[3]. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res, 2004. 94(1): p. 60-7.

[4]. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther, 2007. 21(6): p. 423-9.

Additional Infomation
Therapeutic Uses
Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents
/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Ramipril is included in the database.
Ramipril capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. ... Ramipril capsules may be used alone or in combination with thiazide diuretics. /Included in US product label/
Ramipril capsules are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril capsules to such patients have been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure. /Included in US product label/
For more Therapeutic Uses (Complete) data for Ramipril (8 total), please visit the HSDB record page.
Drug Warnings
/BOXED WARNING/ When pregnancy is detected, discontinue ramipril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue ramipril as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.
Angiotensin-converting enzyme (ACE) inhibitors can cause fetal and neonatal morbidity and mortality when used in pregnancy during the second and third trimesters. ACE inhibitors also increase the risk of major congenital malformations when administered during the first trimester of pregnancy. Discontinue as soon as possible when pregnancy is detected, unless continued use is considered lifesaving. Nearly all women can be transferred successfully to alternative therapy for the remainder of their pregnancy. /Angiotensin-converting enzyme (ACE) inhibitors/
Rare angiotensin-converting enzyme (ACE) inhibitor-associated clinical syndrome manifested initially by cholestatic jaundice may occur; may progress to fulminant hepatic necrosis and is potentially fatal. Patients receiving an ACE inhibitor, including ramipril, who develop jaundice or marked elevations in hepatic enzymes should discontinue the drug and receive appropriate monitoring.
For more Drug Warnings (Complete) data for Ramipril (18 total), please visit the HSDB record page.
Pharmacodynamics
Ramipril is an ACE inhibitor similar to benazepril, fosinopril and quinapril. It is an inactive prodrug that is converted to ramiprilat in the liver, the main site of activation, and kidneys. Ramiprilat confers blood pressure lowing effects by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of ramiprilat by causing increased vasodilation and decreased blood pressure.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C23H32N2O5
Molecular Weight
416.51
Exact Mass
416.231
CAS #
87333-19-5
Related CAS #
Ramipril-d5;1132661-86-9;Ramipril-d3;2673269-81-1
PubChem CID
5362129
Appearance
White to off-white solid powder
Density
1.2±0.1 g/cm3
Boiling Point
616.2±55.0 °C at 760 mmHg
Melting Point
106-108°C
Flash Point
326.4±31.5 °C
Vapour Pressure
0.0±1.9 mmHg at 25°C
Index of Refraction
1.556
LogP
3.41
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
6
Rotatable Bond Count
10
Heavy Atom Count
30
Complexity
619
Defined Atom Stereocenter Count
5
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
InChi Key
HDACQVRGBOVJII-JBDAPHQKSA-N
InChi Code
InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
Chemical Name
(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
Synonyms
HOE-498; Altace; Carasel;HOE498;Ramace; Zabien;HOE 498;Tritace; Ramace; Triatec; Tritace; Vesdil;
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO:83 mg/mL (199.3 mM)
Water:<1 mg/mL
Ethanol:83 mg/mL (199.3 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 3.25 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 3.25 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 3.25 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


Solubility in Formulation 4: 30% PEG400+0.5% Tween80+5% Propylene glycol: 30 mg/mL

Solubility in Formulation 5: 20 mg/mL (48.02 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.4009 mL 12.0045 mL 24.0090 mL
5 mM 0.4802 mL 2.4009 mL 4.8018 mL
10 mM 0.2401 mL 1.2005 mL 2.4009 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
CTID: NCT03475186
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-25
Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
CTID: NCT00933231
Phase: Phase 3    Status: Completed
Date: 2024-11-01
The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction
CTID: NCT05508035
Phase: Phase 3    Status: Recruiting
Date: 2024-10-31
Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions
CTID: NCT00828321
Phase: Phase 1    Status: Completed
Date: 2024-08-19
Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions
CTID: NCT00829530
Phase: Phase 1    Status: Completed
Date: 2024-08-19
View More

Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions
CTID: NCT00829452
Phase: Phase 1    Status: Completed
Date: 2024-08-19


Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
CTID: NCT02842424
Phase: Phase 4    Status: Recruiting
Date: 2024-05-09
Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD
CTID: NCT02008786
Phase: Phase 4    Status: Terminated
Date: 2024-03-15
Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
CTID: NCT06304896
Phase: Phase 1    Status: Not yet recruiting
Date: 2024-03-12
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
CTID: NCT00274599
Phase: Phase 4    Status: Completed
Date: 2023-12-06
Open-label, Multicenter, multinAtionaL, inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients
CTID: NCT06104423
Phase: Phase 4    Status: Recruiting
Date: 2023-10-27
Ramipril for the Treatment of COVID-19
CTID: NCT04366050
Phase: Phase 2    Status: Completed
Date: 2023-09-28
Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data
CTID: NCT04354350
Phase:    Status: Completed
Date: 2023-07-27
Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy Volunteers Under Fasting Conditions
CTID: NCT05438316
Phase: Phase 1    Status: Completed
Date: 2023-06-29
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
CTID: NCT02924727
Phase: Phase 3    Status: Completed
Date: 2023-06-22
Bariatric Surgery and Pharmacokinetics of Ramipril
CTID: NCT03440177
Phase:    Status: Recruiting
Date: 2023-03-07
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
CTID: NCT03715998
Phase: Phase 2    Status: Completed
Date: 2023-02-27
A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril
CTID: NCT03414723
Phase: Phase 1    Status: Completed
Date: 2022-04-25
Explorative Study for Treating Persistent Developmental Stuttering With Ramipril
CTID: NCT04173949
Phase: Phase 3    Status: Unknown status
Date: 2022-03-16
Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease
CTID: NCT03011775
Phase: Phase 4    Status: Completed
Date: 2022-03-10
Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab
CTID: NCT02236806
Phase: Phase 3    Status: Unknown status
Date: 2022-02-01
Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants
CTID: NCT05133050
Phase: N/A    Status: Not yet recruiting
Date: 2021-11-24
REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial
CTID: NCT02499822
Phase: Phase 4    Status: Completed
Date: 2021-09-30
Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)
CTID: NCT03201185
Phase: Phase 4    Status: Unknown status
Date: 2021-09-24
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients
CTID: NCT03991910
Phase: Phase 3    Status: Unknown status
Date: 2021-08-16
Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study
CTID: NCT00421863
Phase: Phase 4    Status: Completed
Date: 2021-02-03
Ramipril in Pediatric Patients on Hemodialysis
CTID: NCT04582097
Phase: Phase 2/Phase 3    Status: Completed
Date: 2020-10-14
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
CTID: NCT00980785
Phase: Phase 4    Status: Completed
Date: 2020-08-25
Nephropathy In Type 2 Diabetes and Cardio-renal Events
CTID: NCT00535925
Phase: Phase 4    Status: Completed
Date: 2020-08-03
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
CTID: NCT02632747
Phase: Phase 2    Status: Completed
Date: 2020-07-24
Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome
CTID: NCT01485978
Phase: Phase 3    Status: Completed
Date: 2020-06-17
African American Study of Kidney Disease and Hypertension
CTID: NCT04364139
Phase: Phase 3    Status: Completed
Date: 2020-04-27
Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination
CTID: NCT04143412
Phase: Phase 2    Status: Unknown status
Date: 2020-01-18
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
CTID: NCT00574834
PhaseEarly Phase 1    Status: Terminated
Date: 2019-09-12
Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus
CTID: NCT03979976
Phase: Phase 2/Phase 3    Status: Completed
Date: 2019-06-10
Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension
CTID: NCT02832973
Phase: Phase 4    Status: Completed
Date: 2019-04-05
Effect of Some Drugs on Liver Fibrosis
CTID: NCT03770936
Phase: Phase 3    Status: Recruiting
Date: 2018-12-10
Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors
CTID: NCT01234922
Phase: Phase 2    Status: Terminated
Date: 2018-08-28
Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions
CTID: NCT00702091
Phase: N/A    Status: Completed
Date: 2018-01-23
Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions
CTID: NCT00702260
Phase: N/A    Status: Completed
Date: 2018-01-23
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
CTID: NCT00281593
Phase: Phase 3    Status: Completed
Date: 2017-12-28
Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
CTID: NCT00608465
Phase: Phase 4    Status: Terminated
Date: 2017-08-11
Ramipril for the Treatment of Oligospermia
CTID: NCT01856361
Phase: N/A    Status: Terminated
Date: 2017-06-02
Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy
CTID: NCT02791958
Phase: Phase 2    Status: Unknown status
Date: 2017-04-10
Cardiac Energetics and Function in Normal Human Ageing
CTID: NCT01504828
Phase: N/A    Status: Completed
Date: 2017-03-30
To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions
CTID: NCT00946621
Phase: Phase 1    Status: Completed
Date: 2017-03-28
Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction
CTID: NCT02525081
Phase: Phase 4    Status: Completed
Date: 2017-02-09
Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
CTID: NCT01078363
Phase: N/A    Status: Completed
Date: 2017-01-26
Doxazosin and Ramipril in Hypertension
CTID: NCT02901977
Phase: Phase 4    Status: Completed
Date: 2016-09-15
Perindopril vs Ramipril for Persistence in MAU Reduction Study
CTID: NCT02729441
Phase: Phase 3    Status: Completed
Date: 2016-04-06
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
CTID: NCT00878969
Phase: Phase 3    Status: Terminated
Date: 2016-02-15
Ramipril Versus Carvedilol in Duchenne and Becker Patients
CTID: NCT00819845
Phase: Phase 4    Status: Unknown status
Date: 2016-01-28
Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
CTID: NCT00736294
Phase: Phase 3    Status: Terminated
Date: 2015-07-28
Aliskiren Study of Safety and Efficacy in Senior Hypertensives
CTID: NCT01922141
Phase: Phase 4    Status: Withdrawn
Date: 2015-04-16
TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
CTID: NCT00905528
Phase:    Status: Completed
Date: 2015-03-25
PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)
CTID: NCT00729365
Phase: Phase 3    Status: Terminated
Date: 2015-03-17
Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants
CTID: NCT01037530
Phase: Phase 4    Status: Completed
Date: 2014-12-19
Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i
CTID: NCT00750308
Phase: N/A    Status: Completed
Date: 2014-12-18
Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus
CTID: NCT00502242
Phase: Phase 4    Status: Completed
Date: 2014-08-27
Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers
CTID: NCT02215005
Phase: Phase 1    Status: Completed
Date: 2014-08-13
Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers
CTID: NCT02214979
Phase: Phase 1    Status: Completed
Date: 2014-08-13
Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers
CTID: NCT02214992
Phase: Phase 1    Status: Completed
Date: 2014-08-13
Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
CTID: NCT01284621
Phase: Phase 1    Status: Completed
Date: 2014-07-22
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
CTID: NCT00153101
Phase: Phase 4    Status: Completed
Date: 2014-05-20
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
CTID: NCT00054938
Phase: Phase 2    Status: Completed
Date: 2013-12-24
Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes
CTID: NCT00240422
Phase: Phase 4    Status: Completed
Date: 2013-11-08
Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM
CTID: NCT00274612
Phase: Phase 4    Status: Completed
Date: 2013-11-01
Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis
CTID: NCT00732069
Phase: Phase 2    Status: Completed
Date: 2013-07-02
Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)
CTID: NCT00141778
Phase: Phase 2/Phase 3    Status: Completed
Date: 2013-03-22
Ramipril - Hypertension
CTID: NCT00325806
Phase: Phase 4    Status: Completed
Date: 2013-03-08
To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy
CTID: NCT01302899
Phase: Phase 2    Status: Terminated
Date: 2013-01-30
Impact of Diabetes on Left Ventricular Remodeling
CTID: NCT01052272
Phase: Phase 2/Phase 3    Status: Completed
Date: 2012-12-17
Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
CTID: NCT01743014
Phase: Phase 4    Status: Unknown status
Date: 2012-12-06
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension
CTID: NCT00760214
Phase: Phase 3    Status: Completed
Date: 2012-11-15
FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients
CTID: NCT01703234
Phase: Phase 4    Status: Completed
Date: 2012-10-10
The RAS, Fibrinolysis and Cardiopulmonary Bypass
CTID: NCT00607672
Phase: Phase 4    Status: Completed
Date: 2012-10-10
A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure
CTID: NCT01005290
Phase: Phase 2    Status: Terminated
Date: 2012-07-26
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
CTID: NCT00923156
Phase: Phase 2    Status: Completed
Date: 2012-07-26
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
CTID: NCT00391846
Phase: Phase 4    Status: Completed
Date: 2012-06-25
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
CTID: NCT00389519
Phase: Phase 3    Status: Ter
A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction
CTID: null
Phase: Phase 2    Status: Ongoing, GB - no longer in EU/EEA, Completed
Date: 2019-07-12
Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment in MINOCA patients - MINOCA-BAT
CTID: null
Phase: Phase 4    Status: Ongoing, Prematurely Ended
Date: 2019-06-24
A Prospective Open-label, Multicentric, Phase IV Trial to Compare the Efficacy of 10-Week Therapy of Ramipril and Indapamide SR Tablets Given Concomitantly with that of the Monotherapy of Ramipril or Indapamide SR in the Treatment of Hypertensive Patients whose Blood Pressure is Not Controlled by Monotherapy
CTID: null
Phase: Phase 4    Status: Completed
Date: 2019-06-12
cGMP Enhancing Therapeutic Strategy for HFpEF: The cGETS Study
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2018-02-28
A multicentre, randomised, open-label, parallel-group trial to study the safety and efficacy
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2018-01-27
Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2017-12-27
PARADISE-MI: Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction
CTID: null
Phase: Phase 3    Status: GB - no longer in EU/EEA, Completed
Date: 2017-03-28
A phase III, international, multicenter, randomized and openlabel study to evaluate the efficacy on LDLc and blood pressure reduction and safety of Trinomia® versus usual care in patients with high cardiovascular risk without previous cardiovascular event. The VULCANO trial.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-02-20
Cardiac toxicity prevention in non-metastatic breast cancer patients treated with anthracycline-based chemotherapy: a randomized, placebo controlled, phase 3 trial - SAFE trial.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2016-08-05
NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease (Pontiac II); a prospective randomized trial
CTID: null
Phase: Phase 4    Status: Ongoing, GB - no longer in EU/EEA
Date: 2015-12-30
REducing blood pressure Variability in Essential hypertension with RAmipril vErsus Nifedipine GITS Trial
CTID: null
Phase: Phase 4    Status: Ongoing, Completed
Date: 2015-02-03
Effect of ACE-Inhibition on Microvascular Function in Women with Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-12-17
A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy
CTID: null
Phase: Phase 4    Status: GB - no longer in EU/EEA
Date: 2014-06-19
A randomized, double-blind, parallel group, active-controlled study to compare the systolic blood pressure lowering efficacy of aliskiren, ramipril and a combination of aliskiren and amlodipine, with an initial 8-week evaluation, followed by a 2-3 year follow-up to compare long-term safety of an aliskiren-based regimen to a ramipril-based regimen in hypertensive patients ? 65 years of age.
CTID: null
Phase: Phase 4    Status: Completed, Prematurely Ended
Date: 2013-12-26
Early prospective therapy trial to delay renal failure in children with Alport syndrome.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2012-02-27
Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2011-11-28
Vitamin D in addition to RAAS blockade and dietary sodium for the Treatment of Urinary Excretion of albumin: the ViRTUE-study
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2011-10-18
Ensayo aleatorizado controlado sobre la terapia guiada por el antígeno carbohidrato 125 en los pacientes dados de alta por insuficiencia cardiaca aguda: efecto sobre la mortalidad a 1 año.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-08-02
Efecto de un fármaco a dosis fija incluyendo ácido acetilsalicílico, una estatina y un inhibidor de enzima convertidora de angiotensina en la adherencia al tratamiento y el control de los factores de riesgo en pacientes post infarto de miocardio
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2011-07-18
Role of renal and systemic vascular resistance for progression of chronic kidney disease
CTID: null
Phase: Phase 4    Status: Completed
Date: 2011-01-03
Renal Hemodynamic Effects of ALiskiren (rasilez) in comparison to ramipril (Tritrace) in patients with overweigHt/obeSiTy and UntreateD hYpertension: The renal HEALTH-STUDY
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2010-10-15
Effects of 6 months intensive vasodilating treatment on vascular resistance and coronary flow reserve in hypertensive patients
CTID: null
Phase: Phase 2    Status: Completed
Date: 2010-07-15
Quantification de la régression de l'albuminurie et de l'atteinte endothéliale dans une population de patients drépanocytaires homozygotes hyperfiltrants traités par inhibiteurs du système rénine-angiotensine - Etude ' RAND '
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2010-07-09
A double blind, randomised, placebo controlled trial to study the clinical effectiveness of Angiotensin Converting Enzyme (ACE) inhibitors, ramipril,in patients with intermittent claudication
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2010-07-09
Cardiovascular Fixed Combination Pill ASR: ensayo clínico farmacodinámico de la combinación a dosis fijas de ácido acetilsalicílico, simvastatina, y ramipril (Cardiovascular Polypill); Colesterol LDL
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2010-07-08
A single-blind, double dummy, randomized, multi-dose, two sequence, crossover, study to investigate the Added effects of Renin Inhibitor (aliskiren 300 mg) on Albuminuria in non-diabetic nephropathy patients treated with ramipril 10 mg and Volume intervention (ARIA)
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2010-06-17
THE ANTITTHROMBOTIC EFFECTS OF DOXAZOSIN AND RAMIPRIL IN ESSENTIAL HYPERTENSION
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2010-06-08
Phase IV prospective, randomized, open with blind endpoints, parallel group study to evaluate the effect of Aliskiren on endothelial dysfunction in patients with essential hypertension
CTID: null
Phase: Phase 4    Status: Completed
Date: 2009-12-11
Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study
CTID: null
Phase: Phase 4    Status: Completed
Date: 2009-11-09
Efficacy of Rasilez® (Aliskiren) compared to ramipril in the treatment of moderate systolic hypertensive patients
CTID: null
Phase: Phase 4    Status: Completed
Date: 2009-06-10
a double blind, double dummy, randomized, multicenter, parallel group study to evaluate the Effects of aliSkiren, ramipril and combination treatment on plasma Concentration of Angiotensin II in Patients with decompensated chronic systolic hEart failure
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-06-04
A randomised controlled trial of the angiotensin converting enzyme inhibitor ramipril in asymptomatic aortic stenosis
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-12-16
Effects of cardioprotective therapy, carvedilol vs ramipril, in patients affected by Duchenne and Becker muscular dystrophy. Clinical significance and prognostic value of Cardiac Magnetic Resonance study.
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2008-12-01
A PROSPECTIVE, RANDOMIZED, OPEN LABEL, BLINDED END-POINT (PROBE) TRIAL TO EVALUATE WHETHER, AT COMPARABLE BLOOD PRESSURE CONTROL, ACE INHIBITOR THERAPY MORE EFFECTIVELY THAN NON RAS INHIBITOR THERAPY REDUCES CARDIOVASCULAR MORBIDITY AND MORTALITY IN CHRONIC DIALYSIS PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY AND/OR ARTERIAL HYPERTENSION (ARCADIA Study)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-11-17
Gene expression profiling in skeletal muscle of healthy subjects treated with ramipril
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-05-13
A Randomozed, Placebo-Controlled Trial of Alagebrium in Patients with Insulin-Dependent Type 1 Diabetes and Microalbuminuria
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2008-05-07
A 54 week, randomized, double-blind, parallel-group, multicenter study evaluating the long-term gastrointestinal (GI) safety and tolerability of aliskiren (300 mg) compared to ramipril (10 mg) in patients with essential hypertension
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-03-06
A Randomised, Placebo Controlled, Double-Blinded Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Translplant Patients Converted to Sirolimus
CTID: null
Phase: Phase 4    Status: Prematurely Ended, Completed
Date: 2008-02-27
A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential Hypertension
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-01-08
RAPAMYCIN FOR TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-12-20
A twelve week, randomized, double-blind, parallel-group multicentre study to evaluate the efficacy and safety of the combination of aliskiren/ramipril/amlodipine (300/10/10mg), compared to the combinations of ramipril/amlodipine (10/10mg) and aliskiren/amlodipine (300/10mg) in patients with essential hypertension and metabolic syndrome not adequately responsive to amlodipine 10mg.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-10-02
The effect of pre-operative Ramipril treatment on vascular inflammation in the abdominal aneurysm
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2007-05-11
Doppler ultrasound investigation of microvasculature in health and disease
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-04-04
Cardiovascular and functional consquences of chronic kidney disease in older people
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-03-15
Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk and an activated inflammation
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-02-12
EVALUATION OF THE EFFICACY OF THE TREATMENT WITH ACE-INHIBITORS ON THE RENAL DAMAGE IN PATIENTS AFFECTED BY GLYCOGEN STORAGE DISEASE TYPE 1 AND OF THE VITAMINE E ON NEUTROPENIA OF PATIENTS WITH GSD1b
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2006-10-11
A nine-week, randomized, double-blind, parallel group study to evaluate the efficacy and safety of aliskiren 300 mg, compared to irbesartan 300 mg and ramipril 10 mg in the setting of a missed dose in patients with essential hypertension
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-05-05
An open-label, multicenter study to evaluate the efficacy and safety of a 5 week therapy with the combination of valsartan 160 mg plus amlodipine 10 mg in hypertensive patients not adequately responding to a 5 week therapy with ramipril 5 mg and felodipine 5 mg
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-11-24
ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuria
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2005-10-18
Efficacy and safety of Olmesartan medoxomil in elderly patients with mild to moderate hypertension
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-08-24
EFFICACY AND SAFETY OF OLMESARTAN IN ELDERLY PATIENTS WITH MILD TO MODERATE HYPERTENSION
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-05-27
Comparison between zofenopril and ramipril in combination with ASA on the extent of cardiovascular risk in patients with systolic left ventricular dysfunction after acute myocardial infarction (SMILE IV trial) - MEN/03/ZOF-CHF/001
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-05-06
A 26 week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing aliskiren to ramipril with optional addition of hydrochlorothiazide (HCTZ), followed by a 4 week double-blind, randomized, placebo-controlled withdrawal in patients with essential hypertension
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-04-12
An eight-week, randomized, double-blind, parallel group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with ramipril in patients with hypertension and diabetes mellitus
CTID: null
Phase: Phase 3    Status: Completed
Date: 2004-12-21
A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril wilse if(down_display === 'none' || down_display === '') { icon_angle_up.style.display = 'none'; icon_angle_down.style.display = 'i

Contact Us